Cargando…

Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction

OBJECTIVE: To investigate the relationship between tumor characteristics and the preoperative counts of immune cells in peripheral blood test in glioma patients. METHODS: We included 260 WHO grades II‐IV patients who had preoperative peripheral blood test result from Sanbo hospital as training set....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhi‐Liang, Zhang, Chuan‐Bao, Liu, Yu‐Qing, Wang, Zheng, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630006/
https://www.ncbi.nlm.nih.gov/pubmed/30912613
http://dx.doi.org/10.1111/cns.13120
Descripción
Sumario:OBJECTIVE: To investigate the relationship between tumor characteristics and the preoperative counts of immune cells in peripheral blood test in glioma patients. METHODS: We included 260 WHO grades II‐IV patients who had preoperative peripheral blood test result from Sanbo hospital as training set. The 66 patients from Tiantan hospital was obtained for validation. RNA sequencing data from CGGA and TCGA datasets were used to evaluate the features of neutrophil subtype and lymphocyte subtype in glioma. RESULTS: We revealed that the count of preoperative lymphocytes, eosinophils and neutrophils were associated with glioma grades. Neutrophil‐to‐lymphocyte ratio (NLR) <3.2 was associated with better prognosis, whereas increased NLR was strongly corresponding with a poor prognosis. Lymphocyte type glioma patients demonstrated a positive correlation with isocitrate dehydrogenase (IDH) mutation and lower grade. IDH mutant glioma contained a higher proportion of tumor‐infiltrating lymphocytes than IDH wild‐type glioma. The immune subtype (neutrophil subtype and lymphocyte subtype) was an independent prognostic factor in glioma. CONCLUSION: Our data demonstrated that NLR was an important prognostic factor in glioma. We classified that the immune subtype of glioma may contribute to a better understanding of disease pathogenesis and lead to the identification of new therapeutic targets for glioma patients.